A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
NCT ID: NCT00208156
Last Updated: 2012-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
87 participants
INTERVENTIONAL
2005-05-31
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
NCT00128479
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
NCT00637494
Optimizing Response in Psychosis Study
NCT00314327
Aripiprazole Once-monthly in Patients With Schizophrenia
NCT01959035
Ziprasidone in the Psychosis Prodrome
NCT00635700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mifepristone
Mifepristone
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mifepristone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are 18 to 75 years of age
* Have a diagnosis of major depressive disorder with psychotic features (DSM-IV 296.24 or 296.34)
* Are able to provide written informed consent
Exclusion Criteria
* Have a history of an allergic reaction to Corlux (C-1073, mifepristone)
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Corcept Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katherine Beebe, PhD
Role: STUDY_DIRECTOR
Corcept Therapeutics
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cnri, Llc
San Diego, California, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
Robert Horne M.D.
Las Vegas, Nevada, United States
CNS Research Institute (CRI)
Clementon, New Jersey, United States
New Jersey Medical School - UMDNJ
Newark, New Jersey, United States
BioBehavioral Health
Toms River, New Jersey, United States
Zucker Hillside Hospital
Glen Oaks, New York, United States
Neurobehavioral Research, Inc.
Lawrence, New York, United States
IPS Research Company
Oklahoma City, Oklahoma, United States
CNS Research Institute (CRI)
Philadelphia, Pennsylvania, United States
Claghorn-Lesem Research Clinic
Bellaire, Texas, United States
International Clinical Research Associates
Richmond, Virginia, United States
Northwest Clinical Research Center
Bellevue, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Belanoff JK, Rothschild AJ, Cassidy F, DeBattista C, Baulieu EE, Schold C, Schatzberg AF. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol Psychiatry. 2002 Sep 1;52(5):386-92. doi: 10.1016/s0006-3223(02)01432-4.
Brogden RN, Goa KL, Faulds D. Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1993 Mar;45(3):384-409. doi: 10.2165/00003495-199345030-00007.
Belanoff JK, Flores BH, Kalezhan M, Sund B, Schatzberg AF. Rapid reversal of psychotic depression using mifepristone. J Clin Psychopharmacol. 2001 Oct;21(5):516-21. doi: 10.1097/00004714-200110000-00009.
Related Links
Access external resources that provide additional context or updates about the study.
Corcept Therapeutics
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
C-1073-10
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.